Abiopharma

🔍 D'Angelo Scott (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 2,873 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 2,873.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 842 shares of Class A Common Stock at $91.6 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: false | shares_owned_after: 2,031.00 | transaction_form_type: 4
• Acquired 1,196 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 3,227.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 351 shares of Class A Common Stock at $91.6 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: false | shares_owned_after: 2,876.00 | transaction_form_type: 4
• Sold 2,873 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 5,750.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3
• Sold 1,196 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: false | shares_owned_after: 2,396.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: The restricted stock units vest in three equal installments on the first, second and third anniversaries of May 1, 2025.
• F3: Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.